Patients diagnosed with vision damage after long-term Elmiron use may qualify to pursue compensation for permanent retinal injuries and medical losses.
Elmiron (pentosan polysulfate sodium) is a prescription medication approved for treatment of interstitial cystitis, a chronic bladder pain condition. For years, the drug was considered safe for long-term use.
Recent ophthalmological studies, however, identified a unique form of retinal damage known as pigmentary maculopathy among patients who used Elmiron for extended periods. Plaintiffs allege manufacturers knew or should have known about these risks but failed to adequately warn patients and healthcare providers.
Cases have been consolidated into federal multidistrict litigation (MDL), allowing courts to evaluate shared scientific evidence while maintaining individual compensation claims.
Researchers discovered that prolonged exposure to Elmiron may damage the retinal pigment epithelium, a critical layer responsible for visual processing. Unlike temporary eye conditions, pigmentary maculopathy may continue to progress even after discontinuation of the drug.
Patients frequently report difficulty reading, dark spots in vision, light sensitivity, and reduced night vision. Diagnostic imaging has revealed distinct retinal patterns strongly associated with cumulative dosage.
Scientific testimony evaluating toxicity mechanisms plays a central role in determining liability and potential settlements.
Degeneration affecting central vision clarity.
Difficulty focusing or reading text.
Reduced vision in low-light environments.
Structural eye injury confirmed by imaging.
Objects appear warped or altered.
Irreversible cases reported.
Used Elmiron for months or years.
Confirmed retinal or macular damage.
Developed symptoms during or after treatment.